Stock Market Reviews

CSTL (Castle Biosciences, Inc.) News

Get the latest news, insights, and market updates on CSTL (Castle Biosciences, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
  KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
  Dec 30, 2025 - $CSTL
• Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
  Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
  Dec 29, 2025 - $CSTL
• MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
  MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
  Dec 29, 2025 - $CSTL
• Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
  SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
  Dec 24, 2025 - $CSTL
• What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
  Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
  Dec 24, 2025 - $CSTL
• FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
  Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
  Dec 24, 2025 - $CSTL
• AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
  Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
  Dec 24, 2025 - $CSTL
• GILD Exercises Option to License Assembly Bio's Herpes Programs
  Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
  Dec 23, 2025 - $CSTL
• AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
  AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
  Dec 23, 2025 - $CSTL
• AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
  AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
  Dec 22, 2025 - $CSTL